WO1994007536A3 - Alginate-bioactive agent conjugates - Google Patents

Alginate-bioactive agent conjugates Download PDF

Info

Publication number
WO1994007536A3
WO1994007536A3 PCT/GB1993/001999 GB9301999W WO9407536A3 WO 1994007536 A3 WO1994007536 A3 WO 1994007536A3 GB 9301999 W GB9301999 W GB 9301999W WO 9407536 A3 WO9407536 A3 WO 9407536A3
Authority
WO
WIPO (PCT)
Prior art keywords
alginate
bioactive agent
agent conjugates
conjugate
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1993/001999
Other languages
French (fr)
Other versions
WO1994007536A2 (en
Inventor
Aymen Al-Shamkhani
Ruth Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keele University
Original Assignee
Keele University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keele University filed Critical Keele University
Priority to DE69333929T priority Critical patent/DE69333929T2/en
Priority to JP6508814A priority patent/JPH08502053A/en
Priority to EP93920995A priority patent/EP0662002B1/en
Priority to US08/406,876 priority patent/US5622718A/en
Priority to CA002145502A priority patent/CA2145502A1/en
Publication of WO1994007536A2 publication Critical patent/WO1994007536A2/en
Publication of WO1994007536A3 publication Critical patent/WO1994007536A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

The invention is an alginate-bioactive agent conjugate connected via an acid labile biodegradable spacer linkage. The conjugate is effective for delivering bioactive agents to targets existing in low-pH environments, either at the target surface or in the target interior.
PCT/GB1993/001999 1992-09-25 1993-09-23 Alginate-bioactive agent conjugates Ceased WO1994007536A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69333929T DE69333929T2 (en) 1992-09-25 1993-09-23 CONJUGATES OF ALGINATE AND BIOACTIVE AGENTS
JP6508814A JPH08502053A (en) 1992-09-25 1993-09-23 Alginate-Bioactive Agent Blend
EP93920995A EP0662002B1 (en) 1992-09-25 1993-09-23 Alginate-bioactive agent conjugates
US08/406,876 US5622718A (en) 1992-09-25 1993-09-23 Alginate-bioactive agent conjugates
CA002145502A CA2145502A1 (en) 1992-09-25 1993-09-23 Alginate-bioactive agent conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9220294A GB2270920B (en) 1992-09-25 1992-09-25 Alginate-bioactive agent conjugates
GB9220294.4 1992-09-25

Publications (2)

Publication Number Publication Date
WO1994007536A2 WO1994007536A2 (en) 1994-04-14
WO1994007536A3 true WO1994007536A3 (en) 1994-07-21

Family

ID=10722516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001999 Ceased WO1994007536A2 (en) 1992-09-25 1993-09-23 Alginate-bioactive agent conjugates

Country Status (7)

Country Link
US (1) US5622718A (en)
EP (2) EP0947202A3 (en)
JP (1) JPH08502053A (en)
CA (1) CA2145502A1 (en)
DE (1) DE69333929T2 (en)
GB (1) GB2270920B (en)
WO (1) WO1994007536A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220414B2 (en) 2000-09-06 2007-05-22 A.P. Pharma, Inc. Degradable polyacetal polymers
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
PL323496A1 (en) * 1995-05-23 1998-03-30 Smithkline Beecham Plc Pharmaceutic composition obtained by adding a taste improving agent to a drug
FR2750864B1 (en) * 1996-07-10 1999-04-16 Oreal USE OF A POLYHOLOSIDE IN A COMPOSITION FOR STIMULATING IMMUNE DEFENSES, AND COMPOSITION COMPRISING SAME
JP4335316B2 (en) * 1996-09-19 2009-09-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Polymers containing polysaccharides such as alginate or modified alginate
EP1806367A3 (en) * 1996-09-19 2007-11-28 The Regents Of The University Of Michigan Polymers containing polysaccharides such as alginates or modified alginates
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
AU7124598A (en) * 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US5939453A (en) * 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
DE19836960A1 (en) * 1998-08-14 2000-02-17 Ulrich Zimmermann Production of high-purity alginate useful for making capsules of encapsulating implants comprises extraction, sedimentation, filtration and precipitation
JP2002527408A (en) * 1998-10-09 2002-08-27 ミシガン大学 Hydrogel and water-soluble polymer carrier for drug delivery
EP1210093A4 (en) * 1999-09-03 2005-01-12 Polytherics Ltd Degradable polymers
WO2002032400A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
DE10112825A1 (en) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
DE10129369C1 (en) * 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Water soluble antibiotic in the form of a polysaccharide conjugate containing an aminosugar
DE10209822A1 (en) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
DE10242076A1 (en) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh New covalently bonded conjugates of hydroxyalkyl starch with allergens, useful as modified allergens with depot effect for use in specific immunotherapy for combating allergies, e.g. hay fever
AU2003260393B2 (en) * 2002-09-11 2009-10-01 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
US20080206182A1 (en) * 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
HRP20110056T1 (en) * 2003-08-08 2011-02-28 Fresenius Kabi Deutschland Gmbh CONJUGATES HYDROXIALKYL STARCH AND G-CSF
EP1758608A2 (en) * 2004-03-11 2007-03-07 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyethyl starch and erythropoietin
AR048035A1 (en) * 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh CONJUGADOS DE ALMIDON DE HIDROXIALQUILO AND A PROTEIN, PREPARED BY REDUCING AMINATION
EP1824459A1 (en) * 2004-12-17 2007-08-29 Medipol S.A. Hydrophilic particles based on cationic chitosan derivatives
SG158175A1 (en) 2004-12-27 2010-01-29 Silence Therapeutics Ag Lipid complexes coated with peg and their use
EP1861124A2 (en) * 2005-03-11 2007-12-05 Fresenius Kabi Deutschland GmbH Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch
CN101495149A (en) * 2005-03-31 2009-07-29 阿帕医药有限公司 PEG-polyacetal diblock and triblock copolymers and pharmaceutical compositions
WO2006105148A2 (en) * 2005-03-31 2006-10-05 Ap Pharma, Inc. Peg-poly(ortho ester) graft copolymers and pharmaceutical compositions
US7767656B2 (en) * 2005-04-25 2010-08-03 Molly S Shoichet Blends of temperature sensitive and anionic polymers for drug delivery
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
US20090060943A1 (en) * 2007-08-31 2009-03-05 O'mara Brendan Joseph Syndrome X Composition and Method of Lowering Blood Pressure and Glycemic Index
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
US8980248B2 (en) 2009-12-18 2015-03-17 The Governing Council Of The University Of Toronto Injectable polymer composition for use as a cell delivery vehicle
ES2912545T3 (en) 2011-06-02 2022-05-26 Massachusetts Inst Technology Modified alginates for cell encapsulation and cell therapy
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CN112999429B (en) 2014-08-01 2022-07-22 麻省理工学院 Modified alginates for anti-fibrotic materials and uses
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US20180147147A1 (en) * 2015-06-03 2018-05-31 Ewos Innovation As Oral delivery system for bioactive agents
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2017004071A1 (en) 2015-06-29 2017-01-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stapled acid-sensitive endosome disrupting alginates
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
AU2016344041B2 (en) 2015-11-01 2019-11-07 Massachusetts Institute Of Technology Materials with improved properties
GB2555391B (en) * 2016-10-21 2019-06-26 Algipharma As Bacitracin-alginate oligomer conjugates
BR112019007927A2 (en) * 2016-10-21 2019-07-02 Algipharma As polymyxin conjugates? alginate oligomers
WO2019090309A1 (en) 2017-11-06 2019-05-09 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5013669A (en) * 1988-06-01 1991-05-07 Smithkline Diagnostics, Inc. Mass producible biologically active solid phase devices

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833729A (en) * 1961-04-24 1974-09-03 Purdue Frederick Co Novel pyrazolidone derivatives in pharmaceutical compositions and methods
US3320236A (en) * 1963-03-07 1967-05-16 Miles Lab Reaction products of polymeric dialdehyde polysaccharides with p-aminosalicylates
GB1174854A (en) * 1967-07-07 1969-12-17 Miles Lab New Biologically Active Conjugates
CH594367A5 (en) * 1974-05-17 1978-01-13 Brenner Beat Max
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5183503A (en) * 1992-05-13 1993-02-02 Greenberg Allen A Method of shaker molding and composition therefor
ZA936692B (en) * 1992-09-12 1994-04-29 Dott Ltd Comp Physiologically active peptide composition
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5013669A (en) * 1988-06-01 1991-05-07 Smithkline Diagnostics, Inc. Mass producible biologically active solid phase devices

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BOYE N P ET AL: "IMMUNOTHERAPY OF TREE POLLEN ALLERGY WITH A MODIFIED ALGINATE CONJUGATED BIRCH POLLEN EXTRACT COMPARED TO AN ALUMINUM ADSORBED EXTRACT.", ALLERGY (CPH), VOL. 45, NO. 4, PAGE(S) 241-248, 1990. *
BRUNO G ET AL: "A MULTICENTER TRIAL OF IMMUNOTHERAPY WITH ALGINATE - CONJUGATED GRASS POLLEN EXTRACT.", ANN ALLERGY, VOL. 56, NO. 5, PAGE(S) 384-391, 1986. *
COIN D ET AL: "A PSEUDOMONAS-AERUGINOSA ALGINATE EXOTOXIN A CONJUGATE THAT ELICITS ANTI- ALGINATE AND EXOTOXIN A-NEUTRALIZING ANTIBODIES.", FEMS (FED EUR MICROBIOL SOC) MICROBIOL IMMUNOL, VOL. 76, NO. 4, PAGE(S) 185-192, 1991. *
CRYZ S J JR ET AL: "PHASE I CLINICAL EVALUATION OF A PSEUDOMONAS-AERUGINOSA ALGINATE -TOXIN A CONJUGATE VACCINE.", HOIBY, N. AND S. S. PEDERSEN (ED.). INTERNATIONAL CONGRESS SERIES, NO., VOL. 977. CYSTIC FIBROSIS, BASIC AND CLINICAL RESEARCH;17TH ANNUAL MEETING OF THE EUROPEAN WORKING GROUP ON CYSTIC FIBROSIS, COPENHAGEN, DENMARK, JUNE 17-21, 1991., pages 159 - 163 *
DIENER E. ET AL: "Specific immunosuppression by immunotoxins containing daunomycin", SCIENCE (USA), 1986, VOL. 231, NO. 4734, PAGE(S) 148-150, *
DILLMAN R O ET AL: "SUPERIORITY OF AN ACID-LABILE DAUNORUBICIN-MONOCLONAL ANTIBODY IMMUNOCONJUGATE COMPARED TO FREE DRUG.", CANCER RES, VOL. 48, NO. 21, PAGE(S) 6097-6102, 1988. *
FRANSSEN E J F ET AL: "LOW-MOLECULAR-WEIGHT PROTEINS AS CARRIERS FOR RENAL DRUG TARGETING.", BIANCHI, C., ET AL. (ED.). CONTRIBUTIONS TO NEPHROLOGY, VOL., VOL. 101. KIDNEY, PROTEINS AND DRUGS: AN UPDATE;7TH INTERNATIONAL SYMPOSIUM OF NEPHROLOGY, MONTECATINI TERME, ITALY, OCTOBER 14-16, 1991, S. KARGER AG: BASEL, CH, pages 99 - 103 *
GAUREAULT R C ET AL: "ERYTHROCYTE MEMBRANE-BOUND DAUNORUBICIN AS A DELIVERY SYSTEM IN ANTICANCER TREATMENT.", ANTICANCER RES, VOL. 9, NO. 4, PAGE(S) 1201-1206, 1989. *
LAVIE E ET AL: "Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.", CANCER IMMUNOL IMMUNOTHER, 1991, VOL. 33, NO. 4, PAGE(S) 223-30, *
MANN J S ET AL: "MOLECULAR AMPLIFIERS SYNTHESIS AND FUNCTIONALIZATION OF A POLYAMINOPROPYLDEXTRAN BEARING A UNIQUELY REACTIVE TERMINUS FOR UNIVALENT ATTACHMENT TO BIOMOLECULES.", BIOCONJUGATE CHEM, VOL. 3, NO. 2, PAGE(S) 154-159, 1992. *
ORTOLANI C ET AL: "EFFICACY OF ONE YEAR OF SPECIFIC IMMUNOTHERAPY SIT WITH AN ALGINATE CONJUGATED PARIETARIA-OFFICINALIS EXTRACT IN PARIETARIA ALLERGIC RHINITIS.", FORTY-FOURTH ANNUAL MEETING OF THE AMERICAN ACADEMY OF ALLERGY AND IMMUNOLOGY, ANAHEIM, CALIFORNIA, USA, MARCH 11-16, 1988.;& J ALLERGY CLIN IMMUNOL, VOL. 81, NO. 1, PAGE(S) 262, 1988. *
PASTORELLO E ET AL: "A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF SPECIFIC IMMUNOTHERAPY WITH ALGINATE CONJUGATED MITE ALPHA FRACTION IN PERENNIAL ALLERGIC RHINITIS.", FORTY-SECOND ANNUAL MEETING OF THE AMERICAN ACADEMY OF ALLERGY AND IMMUNOLOGY, NEW ORLEANS, LA., USA, MAR. 21-26, 1986.;& J ALLERGY CLIN IMMUNOL, VOL. 77, NO. 1 PART 2, PAGE(S) 138, 1986. *
PASTORELO E A ET AL: "EFFECTS OF IMMUNOTHERAPY ON IMMEDIATE AND LATE SPECIFIC NASAL REACTIVITY.", FOLIA ALLERGOL IMMUNOL CLIN, VOL. 37, NO. 3, PAGE(S) 135-142, 1990. *
SHEN, WEI CHIANG ET AL: "cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate", BIOCHEM. BIOPHYS. RES. COMMUN., 102(3), 1048-54, 1981 *
TAYLOR W A ET AL: "ADJUVANT AND SUPPRESSIVE EFFECTS OF GRASS CONJUVAC AND OTHER ALGINATE CONJUGATES ON IMMUNO GLOBULIN G AND IMMUNO GLOBULIN E ANTIBODY RESPONSES IN MICE.", IMMUNOLOGY, VOL. 44, NO. 1, PAGE(S) 41-50, 1981. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220414B2 (en) 2000-09-06 2007-05-22 A.P. Pharma, Inc. Degradable polyacetal polymers
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Also Published As

Publication number Publication date
US5622718A (en) 1997-04-22
GB2270920A (en) 1994-03-30
EP0947202A2 (en) 1999-10-06
CA2145502A1 (en) 1994-04-14
GB2270920B (en) 1997-04-02
WO1994007536A2 (en) 1994-04-14
DE69333929T2 (en) 2006-08-10
EP0662002A1 (en) 1995-07-12
EP0947202A3 (en) 2000-07-12
EP0662002B1 (en) 2005-12-07
JPH08502053A (en) 1996-03-05
GB9220294D0 (en) 1992-11-11
DE69333929D1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
WO1994007536A3 (en) Alginate-bioactive agent conjugates
DE69001730D1 (en) PASTE-SHAPED, AQUEOUS PHARMACEUTICAL COMPOSITIONS.
IE872210L (en) Starburst conjugates
CA2134239A1 (en) Pretargeting methods and compounds
AU7694991A (en) Improved aqueous degreaser compositions
EP0221732A3 (en) Sustained release tablets
ES2020806A4 (en) SHELF SYSTEM.
AU1316092A (en) Polyethylene protein conjugates
AU7581094A (en) Alkylsiloxanes as adjuvants for agriculture
CA2139381A1 (en) Guar as drift control agent
AU4835396A (en) Composition containing nucleic acids, preparation and use
NZ233294A (en) Composition comprising an active ingredient/cyclodextrin inclusion complex
NO905278L (en) FURNITURE FOR FITTING SHEETS.
CA2265767A1 (en) Stable pharmaceutical composition including 4,5-epoxy-morphinan derivative
WO2000042973A3 (en) Homing pro-apoptotic conjugates and methods of using same
AU8033594A (en) Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
DK0426368T3 (en) Preparations containing chitin derivatives to prevent adhesion
DE69009002D1 (en) Vehicle front body construction.
NO900612L (en) PRESERVATIVE FOR Aqueous Compositions.
AU7930691A (en) An aqueous tiecoat composition
CA2255070A1 (en) Novel compounds having antiviral activity
WO2001010408A3 (en) Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
WO2001083520A3 (en) Polyacid glycopeptide derivatives
NO901644L (en) EMULSABLE SOLID PESTICIDE COMPOSITIONS.
HK1047884A1 (en) Biologically active materials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993920995

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2145502

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08406876

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1993920995

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993920995

Country of ref document: EP